Shares of Galectin Therapeutics Inc (NASDAQ:GALT) jumped about 20% on Tuesday after the company announced it had secured a positive regulatory alignment with the U.S. Food and Drug Administration on key elements of a Phase 3 program for belapectin.
Galectin said feedback from a recent Type C meeting with the FDA endorsed the company's approach to advancing belapectin for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis complicated by portal hypertension. The agency and the company agreed on central components of the planned late-stage program, including the study design, the primary endpoint and the overall regulatory framework.
The Phase 3 study will be conducted as a randomized, double-blind, placebo-controlled trial to assess belapectin's safety and efficacy in preventing disease progression. The FDA accepted a composite liver outcome as the primary endpoint for the trial. That composite endpoint includes prevention of development of large esophageal varices - a clinical sign of worsening portal hypertension in patients with compensated MASH cirrhosis.
As part of the agreement, the FDA also accepted Galectin's proposed blinded central review for endoscopic assessments of esophageal varices. That same methodology was employed by the company in its prior global Phase 2b/3 NAVIGATE trial.
Galectin intends to evaluate a single 2 mg dose of belapectin in the upcoming Phase 3, reflecting efficacy signals previously observed with that dose in earlier clinical studies. The company expects the planned trial will be generally similar in size to the NAVIGATE study, given the likeness of the targeted study population.
The FDA clarified that a full approval pathway - the traditional approval route - will be required for the MASH cirrhosis population, rather than the accelerated approval pathway that can be available for earlier-stage MASH populations based on histologic endpoints. The agency indicated the proposed composite outcome endpoints and the overall study framework are appropriate for pursuing full approval.
Looking ahead, Galectin plans to file the Phase 3 protocol in the third quarter of 2026. The company is also exploring strategic and financial partnership opportunities to support continued development and eventual commercialization of belapectin.
Key context and takeaways
- FDA alignment on a composite clinical endpoint and blinded central review supports the Phase 3 study design for belapectin in MASH cirrhosis with portal hypertension.
- The Phase 3 will be randomized, double-blind and placebo-controlled, and will evaluate a single 2 mg dose based on prior observed efficacy.
- Regulatory feedback confirms a traditional approval pathway is required for this population, shaping the evidentiary standard the trial must meet.
Sectors and markets affected
- Biotechnology and biopharmaceutical sectors, as clinical and regulatory developments influence investor sentiment and partner interest.
- Healthcare markets that track late-stage clinical programs for liver disease therapeutics.
Risks and uncertainties
- Regulatory standard - The FDA confirmed a traditional approval pathway is required for the MASH cirrhosis population, which typically requires more comprehensive clinical evidence than accelerated pathways.
- Clinical outcome risk - The Phase 3 trial must demonstrate adequate safety and efficacy using the agreed composite endpoint; the outcome of that trial is not guaranteed.
- Development financing and partnerships - Galectin is exploring strategic and financial partnerships to support development and commercialization, indicating that financing or partner commitments will be relevant to progressing the program.